Zevra Therapeutics, Inc. ( (ZVRA) ) has released its Q4 earnings. Here is a breakdown of the information Zevra Therapeutics, Inc. presented to its investors.
Zevra Therapeutics, Inc. is a commercial-stage company dedicated to developing therapies for rare diseases, utilizing unique data-driven strategies to address unmet medical needs. In its latest financial report, Zevra announced a net revenue of $23.6 million for the fiscal year 2024, with $12.0 million generated in the fourth quarter alone. The company also entered into an asset purchase agreement to sell a Priority Review Voucher for $150 million, marking a significant strategic move.
The company’s financial performance was highlighted by the commercial launch of MIPLYFFA following its FDA approval, contributing $10.1 million to the year’s revenue. Despite a net loss of $105.5 million for the year, Zevra’s strategic initiatives in commercial excellence, pipeline innovation, and talent development are positioning it for future growth. The company also reported a cash position of $75.5 million at the end of 2024, with expectations of extending its cash runway into 2029.
Zevra is actively working on expanding its market presence, with plans to file for regulatory approval of MIPLYFFA in the EU in the second half of 2025. The company is also advancing its clinical trials, including the Phase 3 DiSCOVER trial for celiprolol, aimed at treating Vascular Ehlers-Danlos Syndrome. Additionally, Zevra is exploring strategic alternatives for the development of KP1077 for rare sleep disorders.
Looking ahead, Zevra’s management remains optimistic about the company’s strategic direction and financial health. With the anticipated proceeds from the PRV sale and ongoing commercial efforts, Zevra is well-positioned to continue its mission of delivering transformative therapies for rare disease patients.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com